 Nabiximols seem to be most suitable to our investigation. The co-administration of tetrahydrocannabinol THC with cannabidiol CBD may translate into additional therapeutic benefits with an attenuation of adverse effects. The investigators expect to obtain less sedation, milder high, lower incidence of anxiety, tachycardia, and hyperalgesia, as compared with THC-only acute pain trials. 